Abstract:Lamin A/C gene ( LMNA ) mutations contribute to severe striated muscle laminopathies, affecting cardiac and skeletal muscles, with limited treatment options. In this study, we delve into the investigations of five distinct LMNA mutations, including three novel variants and two pathogenic variants identified in patients with muscular laminopathy. Our approach employs zebrafish models to comprehensively study these variants. Transgenic zebrafish expressing wild-type LMNA and each mutation undergo extensive morphological profiling, swimming behavior assessments, muscle endurance evaluations, heartbeat measurement, and histopathological analysis of skeletal muscles. Additionally, these models serve as platform for focused drug screening. We explore the transcriptomic landscape through qPCR and RNAseq to unveil altered gene expression profiles in muscle tissues. Larvae of LMNA (L35P), LMNA (E358K), and LMNA (R453W) transgenic fish exhibit reduced swim speed compared to LMNA (WT) measured by DanioVision. All LMNA transgenic adult fish exhibit reduced swim speed compared to LMNA (WT) in T-maze. Moreover, all LMNA transgenic adult fish, except LMNA (E358K), display weaker muscle endurance than LMNA (WT) measured by swimming tunnel. Histochemical staining reveals decreased fiber size in all LMNA mutations transgenic fish, excluding LMNA (WT) fish. Interestingly, LMNA (A539V) and LMNA (E358K) exhibited elevated heartbeats. We recognize potential limitations with transgene overexpression and conducted association calculations to explore its effects on zebrafish phenotypes. Our results suggest lamin A/C overexpression may not directly impact mutant phenotypes, such as impaired swim speed, increased heart rates, or decreased muscle fiber diameter. Utilizing LMNA zebrafish models for drug screening, we identify l -carnitine treatment rescuing muscle endurance in LMNA (L35P) and creatine treatment reversing muscle endurance in LMNA (R453W) zebrafish models. Creatine activates AMPK and mTOR pathways, improving muscle endurance and swim speed in LMNA (R453W) fish. Transcriptomic profiling reveals upstream regulators and affected genes contributing to motor dysfunction, cardiac anomalies, and ion flux dysregulation in LMNA mutant transgenic fish. These findings faithfully mimic clinical manifestations of muscular laminopathies, including dysmorphism, early mortality, decreased fiber size, and muscle dysfunction in zebrafish. Furthermore, our drug screening results suggest l -carnitine and creatine treatments as potential rescuers of muscle endurance in LMNA (L35P) and LMNA (R453W) zebrafish models. Our study offers valuable insights into the future development of potential treatments for LMNA -related muscular laminopathy.

mTOR Inhibition Prolongs Survival and Has Beneficial Effects on Heart Function After Onset of Lamin A/C Gene Mutation Cardiomyopathy in Mice

Mammalian target of rapamycin is essential for cardiomyocyte survival and heart development in mice.

Increasing autophagy and blocking Nrf2 suppress laminopathy-induced age-dependent cardiac dysfunction and shortened lifespan

SIRT1 Ameliorates Lamin A/C Deficiency-Induced Cardiac Dysfunction by Promoting Mitochondrial Bioenergetics

Hyperactivation of mTOR and AKT in a cardiac hypertrophy animal model of Friedreich ataxia

Abstract P3207: Mitoregulin Microprotein Influences Mitochondrial Membrane Integrity And Myocardial Ischemia-Reperfusion Injury

mTOR inactivation in myocardium from infant mice rapidly leads to dilated cardiomyopathy due to translation defects and p53/JNK-mediated apoptosis

Non-cell autonomous cardiomyocyte regulation complicates gene supplementation therapy for<i>LMNA</i>cardiomyopathy

Creatine and l-carnitine attenuate muscular laminopathy in the LMNA mutation transgenic zebrafish

Prolong Allograft Survival by Silencing Mtor Gene Using Mannose Liposome in Heart Transplantation.

Lama1 Upregulation Prolongs the Lifespan of the Dyh/dyh Mouse Model of LAMA2-related Congenital Muscular Dystrophy

Up-regulating Autophagy by Targeting the Mtor-4Ebp1 Pathway: a Possible Mechanism for Improving Cardiac Function in Mice with Experimental Dilated Cardiomyopathy

Modulating autophagy improves cardiac function in a rat model of early-stage dilated cardiomyopathy.

Non-cell-Autonomous Cardiomyocyte Regulation Complicates Gene Supplementation Therapy for Lmna-Associated Cardiac Defects in Mice

MTORC1 AND MTORC2 PLAY DIFFERENT ROLES IN THE FUNCTIONAL SURVIVAL OF TRANSPLANTED ADIPOSE-DERIVED STROMAL CELLS IN HINDLIMB ISCHAEMIA MICE VIA REGULATING INFLAMMATION IN VIVO

Dose-dependent effects of mTOR inhibition on weight and mitochondrial disease in mice

Phosphoinositide-Dependent Kinase 1 And Mtorc2 Synergistically Maintain Postnatal Heart Growth And Heart Function In Mice

Activation of PDGF pathway links LMNA mutation to dilated cardiomyopathy

Genetic and Pharmacological Inhibition of Rheb1-Mtorc1 Signaling Exerts Cardioprotection Against Adverse Cardiac Remodeling in Mice

LMNA-related Muscular Dystrophy Involving Myoblast Proliferation and Apoptosis Through the FOXO1/GADD45A Pathway.

Rapamycin Improves Cardiac Function of Myocardial Infarction Mice by Reducing the Expression of Inflammatory Cytokines